[go: up one dir, main page]

WO2005092356A1 - Nouvelle composition a base d'herbes medicinales destinee au traitement du vih/sida et des infections fongiques secondaires liees au vih - Google Patents

Nouvelle composition a base d'herbes medicinales destinee au traitement du vih/sida et des infections fongiques secondaires liees au vih Download PDF

Info

Publication number
WO2005092356A1
WO2005092356A1 PCT/IN2004/000367 IN2004000367W WO2005092356A1 WO 2005092356 A1 WO2005092356 A1 WO 2005092356A1 IN 2004000367 W IN2004000367 W IN 2004000367W WO 2005092356 A1 WO2005092356 A1 WO 2005092356A1
Authority
WO
WIPO (PCT)
Prior art keywords
aids
composition
hiv
hin
bael
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2004/000367
Other languages
English (en)
Inventor
Palaniappan Meenakshisundaram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2005092356A1 publication Critical patent/WO2005092356A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed

Definitions

  • the present invention relates to novel medicinal herbal composition and their use for treating patients with immunological disorders particularly HIV/AIDS .
  • the present invention also relates to the method for treating patients with the medicinal herbal compositioa It works well without conventional antiretroviral and its associated complications and its prohibitive cost and non-compliance.
  • BIN virus is a retro-virus composed of two (2) strands ofR ⁇ A which accesses the human body via blood, semen, and vaginal secretions and occasionally through body fluids and contaminated sharps.
  • -It's viral protein gp 120 locks on with T4 lymphocytes
  • the ADDS and opportunistic infection sets in when the CD4 count drops below 200ul. It is to be appreciated the CD4 (T4 lymphocytes) plays the most and prominent part in the defensive reaction in all types of infections OBJECT OF INVENTION
  • CD4 T4 lymphocytes
  • CD8 count The CD index is determined by dividing CD4 count by CD8 count (CD4/CD8). The opportunistic infection will not manifest when the CD4 count rises above 200 and also the index comes above 1.5.
  • the present invention provides pharmaceutical compositions which contains Indian herbs.
  • the pharmaceutical composition contain as essential herbs Aegle Marmelos (Bael), Wedelia Calendulacea (Bhangra), Withania somnifera (Ashwagandha), and Emblica officinalis (Amla).
  • the preferred weight ratio of Aegle Marmelos (Bael), Wedelia Calendulacea (Bhangra), Withania somnifera (Ashwagandha), and Emblica officinalis (Amla) is 4:2: 1 : 1. Since the composition is relatively inexpensive, produces no adverse side effects, may be taken in multiple daily dose over prolonged periods of time and it results in the control of HIN/AIDS within a few weeks after commencement of ingestion of the composition.
  • the present invention provides pharmaceutical composition which posses' pharmaceutical effects on immunological disorder.
  • the pharmaceutical composition of the invention comprises a mixture of herbs Aegle Marmelos (Bael), Wedelia Calendulacea (Bhangra), Withania somnifera (Ashwagandha), and Emblica officinalis (Amla).
  • Aegle Marmelos (Bael) belongs to the family Rutacea.
  • the medicinal effect of Aegle Marmelos (Bael) is in the leaves.
  • Aegle Marmelos (Bael) can be either collected in wild or cultivated.
  • Aegle Marmelos (Bael) is well available in India .
  • the leaves are shadow dried and powdered and found to have marked and excellent antiretroviral property when used alone and more enhanced action with other herbals and acts more probably at cellular level by interfering at viral enzymes reaction for its DNA formation and viral replication or even earlier br prevention of viral locking of its gp 120 with host T4 lymphocyte by way of defensive coating or otherwise. It is found to have well appreciable antifungal activity either by direct action or by elevation of host resistance or by dual mode and it is ought to be seen to be believed and it goes without and antifungals.
  • Wedelia Calendulacea belongs to the family Compositae.
  • the medicinal effects ofWedelia Calendulacea (Bhangra) is in the entire plant.
  • Wedelia Calendulacea (Bhangra) can be wildely cultivated. It has affinity towards sex organs.
  • the trace amount of heavy metals like Gold and Iron are likely to act at the cellular level in HIV patients similar to Bael leaves and it might potentiate the actions of Bael and itself is potentiated by Amla.
  • Withania Somnifera belongs to the family Solanaceae.
  • the medicinal effects of Withania Somnifera (Ashwagandha) is in the root.
  • Withania Somnifera (Ashwagandha) can be either collected in wild or cultivated and very well available in India.
  • Withania Somnifera (Ashwagandha) shadow dried root is likely to have tonic effect and aphrodisiac effect by virtue of its concentration in pelvic area where HIN retrovirus are found in abundance by which the other antivirals shall have more easy access.
  • Withanolides are otherwise antiinflamatory and anticancerous probably at cellular level and is antianemic since it contains Iron, and its absorption is catalalysed by Amla. Its antioxidant property may probably halt the ageing process more pronounced in HIN patients and may soothen the irritability of early HIN encephalitis.
  • Emblica officinalis belongs to the family Euphorbiaceae. The medicinal effect of Emblica officinalis is in fruit. Emblica officinalis is cultivated wildely and it is antioxidant, anticancerous, antiinflammatory and immunity raising and it might potentiate the actions ofWithania Somnifera and Aegle Marmelos and Wedelia Calendulacea .
  • the composition contains approximately 4:2:1:1 ratio of the above herbs.
  • the composition contains no filler or enhancing agents. Since, such materials are unnecessary and merely serve to dilute the effective concentration of the herbals and to decrease the absorption rate in to the blood-stream after ingestion.
  • the individual herbs obtained from the preferable sources indicated above are cut into pieces, dehydrated (shadow dried), ground, and passed through a sieve and mixed as fine powder to produce herbal mixture.
  • the preferable method of processing the composition of the invention for ingestion is to package the powdered herbal mixture into gelatin capsules (preferably hard gelatin) of a size preferably of the order double zero.
  • gelatin capsules preferably hard gelatin
  • Such hard gelatin capsules are more efficient, economical form of packaging.
  • Tongue ulceration was seen at the tip of the tongue and a map like lesion on its left margin.
  • _ 4 After d 5 days of the treatment, the tongue lesions disappeared. Three months later (November 2002), body weight was 43 kg. Six months later, the patient body weight was 45 Kg. OnApril2003, she weighed 47 kg and CD4 count was 895 and CD8 was 800. On May 2003, she weighed 48 kg and CD4:CD8 ratio is 1.12. On October 2003, she was clinically okay and she was advised to have second count on CD4 and CDS.
  • the patient weight was 13 kg and red papule becomes smaller in size.
  • the patient weight was 14 kg, and lymph nodes disappeared.
  • the patient's fungal infection on the nail beds disappeared. The appearance of the boy dramatically changed in to the state of healthiness and happiness.
  • the patient was 30 years old male diagnosed as HIN positive (Vijaya lab, Karaikudi, Tamil ⁇ adu, India) on July 3,2003 and treatment commenced to the patient after two weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques contenant des herbes médicinales indiennes. Ces compositions sont particulièrement efficaces dans le traitement des patients atteints du VIH/SIDA. L'invention concerne des compositions pharmaceutiques ou des préparations médicinales contenant un mélange constitué des quatre herbes suivantes : Bael (Aegle Marmelos), Bhangra (Wedelia Calendulacea), Aswagandha (Withania Somnifera) et Amla (Emblica Officinalis).
PCT/IN2004/000367 2004-03-25 2004-11-25 Nouvelle composition a base d'herbes medicinales destinee au traitement du vih/sida et des infections fongiques secondaires liees au vih Ceased WO2005092356A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN271CH2004 2004-03-25
IN271/CHE/2004 2004-03-25

Publications (1)

Publication Number Publication Date
WO2005092356A1 true WO2005092356A1 (fr) 2005-10-06

Family

ID=35055983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000367 Ceased WO2005092356A1 (fr) 2004-03-25 2004-11-25 Nouvelle composition a base d'herbes medicinales destinee au traitement du vih/sida et des infections fongiques secondaires liees au vih

Country Status (1)

Country Link
WO (1) WO2005092356A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077100A1 (fr) * 2009-12-24 2011-06-30 Cipla Limited Composition antirétrovirale
WO2018142428A1 (fr) * 2017-02-03 2018-08-09 Hll Lifecare Limited Formulation microbicide à base de plantes pour prévenir le vih

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153198A (en) * 1999-07-13 2000-11-28 Natreon Inc. Withania somnifera composition
US6362167B1 (en) * 1999-02-17 2002-03-26 Natreon Inc. Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions
US20020049251A1 (en) * 1999-12-13 2002-04-25 Zhen Yang Methods for treating cell death diseases and inflammation
WO2002079748A2 (fr) * 2001-02-14 2002-10-10 Bio-Ved Pharmaceuticals, Inc. Withasol et methodes d'utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362167B1 (en) * 1999-02-17 2002-03-26 Natreon Inc. Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions
US6153198A (en) * 1999-07-13 2000-11-28 Natreon Inc. Withania somnifera composition
US20020049251A1 (en) * 1999-12-13 2002-04-25 Zhen Yang Methods for treating cell death diseases and inflammation
WO2002079748A2 (fr) * 2001-02-14 2002-10-10 Bio-Ved Pharmaceuticals, Inc. Withasol et methodes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] RANA B.K. ET AL: "Antifungal activity and kinetics of inhibition by essential oils isolated from leaves of Aegle marmelos.", Database accession no. (9234162) *
J. ETHNOPHARMACOL., vol. 57, no. 1, June 1997 (1997-06-01), pages 29 - 34 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077100A1 (fr) * 2009-12-24 2011-06-30 Cipla Limited Composition antirétrovirale
WO2018142428A1 (fr) * 2017-02-03 2018-08-09 Hll Lifecare Limited Formulation microbicide à base de plantes pour prévenir le vih

Similar Documents

Publication Publication Date Title
US10537600B2 (en) Traditional Chinese medicine combination for regulating immune function and preparation method therefor
US6811796B2 (en) Preventive or therapeutic agent for pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof
JP7069490B2 (ja) ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用
US20090028896A1 (en) Compositions and method for weight loss
AU2004204574A1 (en) Herbal compositions for prostate conditions
CA2517136C (fr) Composition destinee a traiter l'hepatite c
JP2003040787A (ja) 生理活性を有する組成物およびその製造方法
WO2004096252A1 (fr) Compositions et procedes pour perdre du poids
US6746675B2 (en) Physiologically active compositions based upon active ingredients of Basidiomycotina and Araliaceae
WO2005092356A1 (fr) Nouvelle composition a base d'herbes medicinales destinee au traitement du vih/sida et des infections fongiques secondaires liees au vih
CN112891485B (zh) 一种用于新冠肺炎治疗的中药组合物
CN106421366A (zh) 一种具有清咽功能的组合物及其制备方法
JPH09136839A (ja) 生理活性を有する組成物およびその製造方法
CN101721612A (zh) 一种升高白细胞的中药组合物及其制备方法和应用
CN115154538B (zh) 一种具有降血尿酸作用的中药组合物及其应用
CN107865932B (zh) 一种具有减肥功效的中药组合物
CN100443093C (zh) 治疗艾滋病的药物
CN103040909B (zh) 藏药组合物及其在防治酒精性肝病产品制备中的应用
Kemper et al. Astragalus (Astragalus membranaceous)
Abue et al. Using African alternative medicine to curb Covid-19: A case study of SAAAB, SAABFAT6, and SAABMAL HERBAL SUPPLEMENTS
ZA200604983B (en) Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences
CN118975668A (zh) 一种具有养肝护肝作用的药食同源营养组合物及其制备方法及应用
CN120093873A (zh) 一种对结直肠癌免疫治疗有辅助功能的中药组合物及其应用
JPS6233125A (ja) 制癌作用増強剤
CN119770580A (zh) 一种降低血清尿酸水平的组合物、保健食品或药物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase